Only 31% of patients with prostate cancer receiving radiation therapy had a successful CT simulation on the first attempt, while more than half required multiple scans on the same day and nearly 17% ...

With smaller radiation beams, intensity-modulated radiation therapy “takes precision to the next level” for patients with prostate, an expert told CURE®. Intensity-modulated radiation therapy (IMRT) — ...

Using MRI instead of CT guidance to zero in on prostate tumors enables more precise delivery of SBRT and lowers side effect rates. MRI vs CT guidance reduces side effects from prostate cancer ...

When planning for palliative radiotherapy, clinicians can forgo an additional CT scan on the same day as treatment and instead use a recent diagnostic CT scan, according to a results from a randomized ...

Approximately 20% to 40% of men who have surgery for localized prostate cancer will see the cancer return within 10 years, often first detected by a rising PSA blood test. When this happens, doctors ...

For many men with prostate cancer, weeks of daily treatments are no longer the norm. Jonathan Tward, MD, a radiation oncologist at Huntsman Cancer Institute, explains how image guidance, real-time ...

New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term value Philips debuts helium-free [2] BlueSeal RT 1.5T 70cm MR ...

If you or a loved one has been diagnosed with prostate cancer, you’re not alone—and you don’t have to wait long to take the next step. Whether you’re newly diagnosed, moving from active surveillance ...

Reviewed by Peter E. Lonergan, MD, FRCS (Urol.), consultant urologist and clinical senior lecturer at St. James’s Hospital & Trinity College in Dublin, Ireland. If you have prostate cancer and ...

Prostate cancer is one of the most common cancers worldwide and remains a significant cause of cancer-related death. With increasing life expectancy, its incidence is projected to rise steadily in the ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...